Cetera Advisor Networks LLC Acquires 2,606 Shares of Eli Lilly and Company (NYSE:LLY)

Cetera Advisor Networks LLC grew its position in Eli Lilly and Company (NYSE:LLYGet Rating) by 7.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,249 shares of the company’s stock after purchasing an additional 2,606 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Eli Lilly and were worth $12,725,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Eli Lilly and by 1.8% during the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after buying an additional 1,219,424 shares in the last quarter. Capital World Investors increased its stake in shares of Eli Lilly and by 17.0% in the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after acquiring an additional 3,242,548 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Eli Lilly and by 31.1% in the 2nd quarter. Jennison Associates LLC now owns 10,358,066 shares of the company’s stock valued at $3,358,396,000 after acquiring an additional 2,456,760 shares during the last quarter. Capital International Investors increased its stake in shares of Eli Lilly and by 30.5% in the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock valued at $2,532,024,000 after acquiring an additional 2,063,557 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in shares of Eli Lilly and by 7.5% in the 1st quarter. Fisher Asset Management LLC now owns 7,504,205 shares of the company’s stock valued at $2,148,979,000 after purchasing an additional 521,295 shares during the period. Institutional investors own 82.45% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. Argus upped their price target on Eli Lilly and from $315.00 to $360.00 in a research report on Friday, September 30th. The Goldman Sachs Group increased their price target on Eli Lilly and from $281.00 to $313.00 and gave the company a “neutral” rating in a research note on Tuesday, November 8th. Truist Financial increased their price objective on Eli Lilly and from $400.00 to $421.00 in a research report on Tuesday, November 15th. SVB Leerink increased their price objective on Eli Lilly and from $341.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 2nd. Finally, Wells Fargo & Company increased their target price on Eli Lilly and from $305.00 to $365.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 2nd. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and has an average rating of “Moderate Buy” and an average target price of $355.89.

Eli Lilly and Price Performance

Shares of Eli Lilly and stock opened at $361.67 on Monday. The business’s 50-day moving average price is $335.81 and its 200-day moving average price is $320.01. The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 1.39. Eli Lilly and Company has a 12 month low of $231.87 and a 12 month high of $369.80. The firm has a market capitalization of $343.65 billion, a PE ratio of 54.30, a price-to-earnings-growth ratio of 2.28 and a beta of 0.36.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be given a dividend of $0.98 per share. The ex-dividend date of this dividend is Monday, November 14th. This represents a $3.92 annualized dividend and a yield of 1.08%. Eli Lilly and’s payout ratio is 58.86%.

Insider Transactions at Eli Lilly and

In other news, major shareholder Lilly Endowment Inc sold 400 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 12th. The stock was sold at an average price of $333.50, for a total value of $133,400.00. Following the sale, the insider now directly owns 103,624,146 shares in the company, valued at approximately $34,558,652,691. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $326.23, for a total value of $214,006.88. Following the sale, the executive vice president now directly owns 6,950 shares in the company, valued at approximately $2,267,298.50. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, October 12th. The shares were sold at an average price of $333.50, for a total value of $133,400.00. Following the completion of the transaction, the insider now owns 103,624,146 shares of the company’s stock, valued at approximately $34,558,652,691. The disclosure for this sale can be found here. In the last three months, insiders have sold 571,297 shares of company stock worth $193,929,777. 0.12% of the stock is currently owned by insiders.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.